Advancing treatment for BPDCN: current therapies, a deep dive into tagraxofusp, & emerging novel agents

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy characterized by involvement of the skin, bone marrow, and lymph nodes, often associated with a poor prognosis. In this podcast episode, Naveen Pemmaraju, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, provides an in-depth exploration of BPDCN. Dr Pemmaraju discusses the challenges in treating this disease and reviews current therapeutic options such as chemotherapy, tagraxofusp, and transplantation. He takes a deep dive into the CD123-targeted agent tagraxofusp, addressing patient eligibility, the role of tagraxofusp in bridging to transplantation, and real-world data on its use. Additionally, Dr Pemmaraju shares insights into ongoing clinical trials and emerging treatments for BPDCN, including novel CD123-targeted therapies, combination strategies, BCL2 inhibitors, and immunotherapeutic approaches.